Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans

British Journal of Clinical Pharmacology

Volumn 55, Issue 1, 2003, Pages 77-85

  Wang, Zaiqi ^a   Hall, Stephen D ^a   Maya, Juan F ^a   Li, Lang ^a   Asghar, Ali ^a   Gorski, J Christopher ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chlorzoxazone; CYP2E1; Diabetes; Insulin

Indexed keywords

6 HYDROXYCHLORZOXAZONE; CHLORZOXAZONE; CHOLESTEROL; CYTOCHROME P450 2E1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; KETONE DERIVATIVE; LIVER ENZYME; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

ADOLESCENT; ADULT; AGED; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DNA, COMPLEMENTARY; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA;

EID: 0037241174     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01731.x     Document Type: Article

References (37)

1. Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6: 1-42.
2. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22: 1-21.
3. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4: 168-179.
4. Surbrook SE Jr, Olson MJ. Dominant role of cytochrome P-450 2E1 in human hepatic microsomal oxidation of the CFC-substitute 1,1,1,2-tetrafluoroethane. Drug Metab Dispos 1992;20: 518-524.
5. Peter R, Bocker R, Beaune PH et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3: 566-573.
6. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993;79: 795-807.
7. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27: 128-133.
8. Niemela O, Parkkila S, Juvonen RO et al. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol 2000;33: 893-901.
9. Barnett CR, Petrides L, Wilson J, Flatt PR, Ioannides C. Induction of rat hepatic mixed-function oxidases by acetone and other physiological ketones: their role in diabetes-induced changes in cytochrome P450 proteins. Xenobiotica 1992;22: 1441-1450.
10. Shimojo N, Ishizaki T, Imaoka S et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 1993;46: 621-627.
11. Song BJ, Veech RL, Saenger P. Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. J Clin Endocrinol Metab 1990;71: 1036-1040.
12. Lucas D, Farez C, Bardou LG et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998;12: 553-558.
13. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997;27: 243-256.
14. Asghar A, Haehner-Daniels BD, Gorski JC, Hall SD. Induction of MDR1 and cytochrome P450 mRNAs by rifampin in human mononuclear cells. Drug Metab Dispos 2002;30: 20-26.
15. Desiraju RK, Renzi NL Jr, Nayak RK, Ng KT. Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983;72: 991-994.
16. Ono S, Hatanaka T, Hotta H et al. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995;5: 143-150.
17. Berthou F, Goasduff T, Lucas D et al. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995;5: 72-79.
18. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001;52: 555-561.
19. Zhu B, Ou-Yang DS, Chen XP et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001;70: 455-461.
20. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993;45: 1563-1569.
21. Dupont I, Lucas D, Clot P, Menez C, Albano E. Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics. J Hepatol 1998;28: 564-571.
22. Koop DR, Coon MJ. Ethanol oxidation and toxicity: role of alcohol P-450 oxygenase. Alcohol Clin Exp Res 1986; 10 (6 Suppl): 44S-49S.
23. Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105: 1067-1075.
24. Raucy JL, Lasker JM, Kraner JC et al. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991;39: 275-280.
25. Brouwer KL, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. II.In vivo and in vitro assessments of microsomal enzyme induction. J Pharmacol Exp Ther 1984;231: 654-659.
26. Enriquez A, Leclercq I, Farrell GC, Robertson G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999;255: 300-306.
27. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111: 1645-1653.
28. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998;28: 410-416.
29. Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 1990;268: 765-769.
30. Shimojo N. Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 1994;26: 1261-1268.
31. Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989; 264: 3568-3572.
32. Favreau LV, Malchoff DM, Mole JE, Schenkman JB. Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J Biol Chem 1987;262: 14319-14326.
33. Leclercq I, Horsmans Y, Desager JP, Pauwels S, Geubel AP. Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity. Br J Nutr 1999;82: 257-262.
34. Woodcroft KJ, Hafner MS, Novak RF. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 2002;35: 263-273.
35. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56: 359-367.
36. Zhang QY, Dunbar D, Ostrowska A et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999;27: 804-809.
37. Raucy JL, Schultz ED, Wester MR et al. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997;25: 1429-1435.